Plain-English translation of NCT00872495 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are developing a new urine-based test to detect bladder cancer by looking for specific genetic mutations in cells shed in the urine. This test could potentially catch bladder cancer earlier and more reliably than current methods. The study will compare this new test against standard procedures like cystoscopy and traditional urine cytology.
Bladder cancer often comes back after initial treatment, and current detection methods aren't always reliable. Doctors need a simple, non-invasive way to find cancer early and monitor patients for recurrence, which could improve survival rates and quality of life.
You likely qualify if…
You likely don't qualify if…
If you have bladder cancer, you'll provide two urine samples on the day of your scheduled bladder procedure—one through normal urination and one collected by catheter during surgery. You may also be asked to provide additional urine samples at follow-up visits over the next two years. If you're in the control group (no bladder cancer), you'll simply provide one urine sample during a regular clinic visit. All samples are non-invasive and require no medication or special procedures beyond standard urine collection.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States
Enrollment target
~500 participants
Started
September 2002
Primary completion
October 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kimberly Rieger-Christ, PhD
Lahey Clinic, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.